Oncology News and Research

RSS
Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita commences IND-enabling studies for its first oncology drug candidate

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Good Samaritan Hospital's Stroke Program certified as primary stroke center

Good Samaritan Hospital's Stroke Program certified as primary stroke center

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies

Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Energy drink manufacturers market their products on TV channels that appeal to teen audiences

Energy drink manufacturers market their products on TV channels that appeal to teen audiences

New drug shows potential against rare type of acute leukemia

New drug shows potential against rare type of acute leukemia

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Researchers identify bio-markers that could help detect early stage colorectal cancer

Researchers identify bio-markers that could help detect early stage colorectal cancer

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Combination treatment improves outcomes in women with ovarian cancer

Combination treatment improves outcomes in women with ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.